Clinical Trials Sponsored by IRIS Media Inc

Total 81 results

IRIS Media Inc

Completed

ASD Parent Trainer: Online Coaching for Parents of Children With Autism (APT)

Autism Disorder

United States
IRIS Media Inc
Spelman College

Completed

Culturally Responsive Stress Reduction: A Mobile Mindfulness Application for African Americans (CRSR) (CRSR)

Behavior

United States
Tris Pharma, Inc.

Completed

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

Diabetic Polyneuropathy

Germany, United Kingdom
Tris Pharma, Inc.

Terminated

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (CORAL)

Neoplasms | Pain | Chronic Pain

Croatia, Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Chile, Spain, United Kingdom
Tris Pharma, Inc.

Completed

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Tris Pharma, Inc.

Completed

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Attention Deficit Hyperactivity Disorder

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
Laboratoires Thea
Iris Pharma; Axial Biotech, Inc

Completed

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice (MEIBUM)

Meibomian Gland Dysfunction | Ocular Surface Disease | Palpebral Pathologies

Germany, Spain
Tris Pharma, Inc.

Not yet recruiting

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy (ALLEVIATE2)

Acute Pain

United States
Tris Pharma, Inc.

Completed

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Pain

Netherlands
Tris Pharma, Inc.

Completed

Assessment of Abuse Potential of Cebranopadol in Humans

Human Abuse Potential

United States
Tris Pharma, Inc.

Completed

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Abuse, Drug

Canada
Tris Pharma, Inc.

Completed

Bunionectomy Trial With GRT6005

Post Operative Pain

United States
Tris Pharma, Inc.

Completed

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Diabetes Mellitus | Diabetic Neuropathies | Chronic Pain

France, Spain, Austria, United States, Denmark, Germany, Italy, Netherlands
Tris Pharma, Inc.

Completed

CORAL XT - Open-label Extension Trial of the CORAL Trial (CORAL XT)

Neoplasms | Pain | Chronic Pain

Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia
Tris Pharma, Inc.

Completed

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

Attention Deficit Hyperactivity Disorder

United States
Recros Medica, Inc.

Completed

The PREFORM Study: Rotational Fractional Resection for Submental Contouring

Lipodystrophy | Skin Laxity

United States
Mirabilis Medica, Inc.

Unknown

Directed Ablation of Uterine Fibroids Using a Noninvasive Approach (DIANA)

Uterine Leiomyoma
Mirabilis Medica, Inc.

Completed

Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids

Uterine Fibroids (Leiomyomas)

Mexico
Gamma Medica, Inc.

Withdrawn

MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue

Breast Neoplasms
Recros Medica, Inc.

Unknown

The INFORM Study: Rotational Fractional Resection for Submental Contouring

Skin Laxity

United States
Recros Medica, Inc.

Completed

CONFORM: Rotational Fractional Resection for Submental Contouring

Lipodystrophy | Skin Laxity

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Low Back Pain

Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
Tris Pharma, Inc.
Forest Laboratories

Completed

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Prolonged QTc Interval | Pharmacokinetic

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

Pain | Diabetic Neuropathies

Bulgaria, Germany, Romania
Tris Pharma, Inc.
Forest Laboratories

Completed

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

Osteoarthritis of the Knee

Austria, Poland, Spain
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Pharmacokinetic

United States
Tris Pharma, Inc.
Premier Research Group plc

Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

ADHD

United States
Meda Pharmaceuticals
TKL Research, Inc.

Completed

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

Herpes Labialis

United States
Mylan Inc.
Meda Pharma S.p.A.

Recruiting

Study to Evaluate the Effectiveness of Legalon®

Non-alcoholic Fatty Liver Disease (NAFLD)

Thailand
NewAmsterdam Pharma
Pharma Medica Research, Inc.

Completed

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

Healthy Volunteers

Canada
Altamira Medica Ltd.

Completed

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Rhinitis, Allergic | Perennial Allergic Rhinitis

Canada
Mylan Inc.
MEDA Pharma GmbH & Co. KG

Completed

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

Allergic Rhinitis

Taiwan, Thailand, Malaysia, Hong Kong
Irish Response t/a Lifes2good
Stephens & Associates, Inc.

Completed

To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

Hair Thinning

United States
MEDA Pharma GmbH & Co. KG

Completed

Dymista Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

Aldara for the Treatment of Large and/or Multiple sBCC

Carcinoma, Basal Cell

France
MEDA Pharma GmbH & Co. KG

Completed

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Germany
MEDA Pharma GmbH & Co. KG

Completed

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Genital Warts

Italy
MEDA Pharma GmbH & Co. KG

Completed

Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions

Actinic Keratosis

France
Chonbuk National University Hospital
Medi Image, Inc

Unknown

A Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of Brain Magnetic Resonance Imaging, and Carotid Doppler Ultrasound

Cerebral Blood Flow

Korea, Republic of
MEDA Pharma GmbH & Co. KG

Completed

MP-AzeFlu Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

DYmista NAsal Spray in CHInese Patients (DYNAS-CHI)

Allergic Rhinitis

China
MEDA Pharma GmbH & Co. KG

Completed

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA)

Actinic Keratosis

Austria, Germany, France
MEDA Pharma GmbH & Co. KG

Completed

To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

Atrial Fibrillation

France
MEDA Pharma GmbH & Co. KG

Recruiting

Real-world Evidence Study on Cystistat (IC/BPS)

Interstitial Cystitis and Bladder Pain Syndrome

Austria
MEDA Pharma GmbH & Co. KG

Completed

Azelastine Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Germany
MEDA Pharma GmbH & Co. KG

Completed

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Actinic Keratoses
MEDA Pharma GmbH & Co. KG

Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients

Actinic Keratosis

Clinical Trials Sponsored by IRIS Media Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations